<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809276</url>
  </required_header>
  <id_info>
    <org_study_id>J0844</org_study_id>
    <secondary_id>NA_00017193</secondary_id>
    <nct_id>NCT00809276</nct_id>
  </id_info>
  <brief_title>Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY</brief_title>
  <official_title>Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to find the most effective and least toxic way to prevent
      GVHD after BMT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A person who has cancer of the blood or lymph glands can be treated by bone marrow
      transplantation (BMT). BMT has developed over several decades of research on both animal and
      human subjects as an effective treatment of various malignant and nonmalignant hematologic
      diseases. Many hematologic malignancies can be successfully treated with a combination of
      high-dose chemotherapy or chemo-radiotherapy and transplantation of allogeneic bone marrow or
      peripheral blood stem cells (alloBMT)

      However, a possible side effect of BMT is graft versus host disease (GVHD). GVHD occurs when
      cells of the donor's immune system, which are present in the bone marrow, attack the BMT
      recipient's normal tissue. Prevention of GVHD is important for the success of the bone marrow
      transplant. This research is being done to find the most effective and least toxic way to
      prevent GVHD after BMT
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine the Optimal Regimen of Post-graft Immunosuppression With High-dose Cy Following Fludarabine, Busulfan, and Transplantation of Fully HLA-matched Bone Marrow That Leads to an Acceptable Incidence of Grades III/IV Acute GVHD</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants with grade III-IV acute graft versus host disease (GVHD). GVHD is graded on a combination of skin symptoms (rash), gut symptoms (diarrhea), and liver symptoms (using a lab test called bilirubin). Grades range from I to IV, where I is the least severe and IV is the most severe.</description>
  </primary_outcome>
  <enrollment type="Actual">92</enrollment>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan, Fludarabine, Cytoxan</intervention_name>
    <description>Busulfan once a day for 4 days
Fludarabine once a day for 4 days
Bone marrow transplant
Cytoxan two doses</description>
    <other_name>BMT</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Allogeneic</other_name>
    <other_name>Transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ages between 0 to and 65 years of age.

          -  Patient must have a genotypically HLA-identical sibling, a phenotypically matched
             first-degree relative or an unrelated matched donor.

          -  Acute lymphocytic leukemia (ALL) in CR1 with high risk features

          -  Acute myeloid leukemia (AML) in CR1 with high risk features defined as:

             i. Greater than 1 cycle of induction therapy required to achieve remission, ii.
             Preceding myelodysplastic syndrome (MDS) other than myelofibrosis, secondary AML iii.
             Presence of Flt3 mutations or internal tandem duplications, iv. FAB M6 or M7
             classification or adverse cytogenetics for overall survival such as those associated
             with MDS, M6, M7 leukemia, or v. Complex karyotype [&gt; 3 abnormalities]

          -  Acute Leukemias in 2nd or greater remission

          -  Refractory or Relapsed AML

          -  AML transformed from MDS

          -  Myelodysplastic syndrome (MDS) beyond refractory anemia

          -  Chronic myeloid leukemia (CML)

          -  Chronic myelomonocytic leukemia

          -  Philadelphia-negative myeloproliferative disorder

          -  Relapsed chemotherapy-sensitive Hodgkin's or Non-Hodgkin's lymphoma

          -  Multiple Myeloma-Stage III

        Exclusion Criteria:

          -  Prior autologous or allogeneic stem cell transplant.

          -  Performance status greater than 2

          -  Active infection.

          -  Inadequate cardiac function; arrythmias or symptomatic cardiac disease.

          -  Inadequate pulmonary function; FEV1, FVC, DLCO &lt;50% of predicted

          -  Inadequate Serum creatinine clearance &lt;60

          -  InadequatebHepatic function

          -  Positive serology for HIV-1, 2 or HTLV-1, 2.

          -  Pregnancy. Female patient must have negative pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo Luznik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Sydney Kimmel Comprehensive Cancer center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marcos deLima, MD</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul V. O'Donnell, M.D., Ph.D.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <results_first_submitted>December 19, 2014</results_first_submitted>
  <results_first_submitted_qc>January 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2015</results_first_posted>
  <last_update_submitted>January 29, 2015</last_update_submitted>
  <last_update_submitted_qc>January 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute lymphocytic leukemia (ALL)</keyword>
  <keyword>Acute myeloid leukemia (AML)</keyword>
  <keyword>Acute Leukemia</keyword>
  <keyword>Refractory or Relapsed AML</keyword>
  <keyword>Myelodysplastic syndrome (MDS)</keyword>
  <keyword>Chronic myeloid leukemia (CML)</keyword>
  <keyword>Chronic myelomonocytic leukemia</keyword>
  <keyword>Hodgkin's Lymphoma</keyword>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>Philadelphia-negative myeloproliferative disorder</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Bone Marrow</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Related donor</keyword>
  <keyword>unrelated donor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BuFlu Transplant</title>
          <description>Myeloablative bone marrow transplant with busulfan and fludarabine conditioning Post-transplantation cyclophosphamide as single-agent graft-versus-host-disease prophylaxis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BuFlu Transplant</title>
          <description>Myeloablative bone marrow transplant with busulfan and fludarabine conditioning Post-transplantation cyclophosphamide as single-agent graft-versus-host-disease prophylaxis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="21" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Determine the Optimal Regimen of Post-graft Immunosuppression With High-dose Cy Following Fludarabine, Busulfan, and Transplantation of Fully HLA-matched Bone Marrow That Leads to an Acceptable Incidence of Grades III/IV Acute GVHD</title>
        <description>Percentage of participants with grade III-IV acute graft versus host disease (GVHD). GVHD is graded on a combination of skin symptoms (rash), gut symptoms (diarrhea), and liver symptoms (using a lab test called bilirubin). Grades range from I to IV, where I is the least severe and IV is the most severe.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BuFlu Transplant</title>
            <description>Myeloablative bone marrow transplant with busulfan and fludarabine conditioning Post-transplantation cyclophosphamide as single-agent graft-versus-host-disease prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Optimal Regimen of Post-graft Immunosuppression With High-dose Cy Following Fludarabine, Busulfan, and Transplantation of Fully HLA-matched Bone Marrow That Leads to an Acceptable Incidence of Grades III/IV Acute GVHD</title>
          <description>Percentage of participants with grade III-IV acute graft versus host disease (GVHD). GVHD is graded on a combination of skin symptoms (rash), gut symptoms (diarrhea), and liver symptoms (using a lab test called bilirubin). Grades range from I to IV, where I is the least severe and IV is the most severe.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="8" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 100 days after bone marrow transplant.</time_frame>
      <desc>Systematically monitored through at least Day 60.</desc>
      <group_list>
        <group group_id="E1">
          <title>BuFlu Transplant</title>
          <description>Myeloablative bone marrow transplant with busulfan and fludarabine conditioning Post-transplantation cyclophosphamide as single-agent graft-versus-host-disease prophylaxis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Primary graft failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Secondary graft failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Diffuse alveolar hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Gastritis and ileitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>ALT elevation grade 3-4</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>AST elevation grade 3-4</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia grade 3-4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase elevated grade 3-4</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Renal toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic pulmonary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythroderma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>AST elevation grade 3-4</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>ALT elevation grade 3-4</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Engraftment &gt; Day 28</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia grade 3-4</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Leo Luznik, MD</name_or_title>
      <organization>SKCCC</organization>
      <phone>410-502-7732</phone>
      <email>lluznik2@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

